| Waldenstrom Macroglobulinemia
Brukinsa vs Imbruvica
Side-by-side clinical, coverage, and cost comparison for waldenstrom macroglobulinemia.Deep comparison between: Brukinsa vs Imbruvica with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsImbruvica has a higher rate of injection site reactions vs Brukinsa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Imbruvica but not Brukinsa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Brukinsa
Imbruvica
At A Glance
Oral
Once or twice daily
BTK inhibitor
Oral
Once daily
BTK inhibitor
Indications
- Mantle cell lymphoma
- Waldenstrom Macroglobulinemia
- Marginal Zone B-Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Lymphoma, Follicular
- leukemia
- Waldenstrom Macroglobulinemia
- Graft-vs-Host Disease
Dosing
Mantle cell lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 160 mg orally twice daily or 320 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.
Lymphoma, Follicular 160 mg orally twice daily in combination with obinutuzumab, with or without food, until disease progression or unacceptable toxicity.
leukemia, Waldenstrom Macroglobulinemia 420 mg orally once daily until disease progression or unacceptable toxicity.
Graft-vs-Host Disease (age >= 12 years) 420 mg orally once daily until cGVHD progression, recurrence of underlying malignancy, or unacceptable toxicity.
Graft-vs-Host Disease (age 1 to < 12 years) 240 mg/m2 orally once daily (up to 420 mg) until cGVHD progression, recurrence of underlying malignancy, or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=30%) Neutrophil count decreased, platelet count decreased, upper respiratory tract infection, hemorrhage, musculoskeletal pain
Serious Hemorrhage, pneumonia, cytopenias, second primary malignancies, cardiac arrhythmias, hepatotoxicity including drug-induced liver injury
Postmarketing Drug-induced liver injury
Most common (>=30%) thrombocytopenia, diarrhea, fatigue, musculoskeletal pain, neutropenia, rash, anemia, bruising, nausea
Serious hemorrhage, infections, cardiac arrhythmias, cardiac failure, sudden death, hypertension, cytopenias, second primary malignancies, hepatotoxicity including DILI, tumor lysis syndrome
Postmarketing hepatic failure, hepatic cirrhosis, drug-induced liver injury, interstitial lung disease, tumor lysis syndrome, anaphylactic shock, angioedema, urticaria, Stevens-Johnson Syndrome, onychoclasis, panniculitis, neutrophilic dermatoses, cutaneous vasculitis, hepatitis B reactivation, peripheral neuropathy, uveitis
Pharmacology
Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK) that forms a covalent bond with a cysteine residue in the BTK active site, inhibiting BTK activity and thereby blocking B-cell proliferation, trafficking, chemotaxis, and adhesion pathways driven by B-cell antigen receptor and cytokine receptor signaling.
Ibrutinib is a small-molecule BTK inhibitor that forms a covalent bond with a cysteine residue in the BTK active site, inhibiting BTK enzymatic activity and blocking B-cell antigen receptor and cytokine receptor signaling pathways necessary for B-cell trafficking, chemotaxis, and adhesion.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Brukinsa
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Imbruvica
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (10/12) · Qty limit (11/12)
UnitedHealthcare
Brukinsa
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (5/8) · Qty limit (4/8)
Imbruvica
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (8/8)
Humana
Brukinsa
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Imbruvica
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Brukinsa.
No savings programs available for Imbruvica.
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BrukinsaView full Brukinsa profile
ImbruvicaView full Imbruvica profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.